Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer (Q36663677)
Jump to navigation
Jump to search
scientific article published on 14 February 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer |
scientific article published on 14 February 2013 |
Statements
1 reference
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer (English)
1 reference
V Heinemann
1 reference
M P Ebert
1 reference
R P Laubender
1 reference
P Bevan
1 reference
C Mala
1 reference
S Boeck
1 reference
14 February 2013
1 reference
1 reference
766-770
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference